Medicus Pharma (NASDAQ: MDCX) has announced successful results from its Phase 2 clinical trial evaluating a non-invasive treatment for basal cell carcinoma. The study utilized a doxorubicin microneedle array (D-MNA) delivery system, representing a significant advancement in non-surgical chemotherapy. According to the report, the highest-dose group achieved a 73% clinical clearance rate of cancerous lesions. The randomized, placebo-controlled trial involved 90 patients suffering from nodular basal cell carcinoma to evaluate the efficacy of the treatment. These positive results mark a critical milestone for the biotech firm, potentially paving the way for future commercialization. Investors are closely monitoring the company as it moves closer to providing a viable alternative to traditional invasive procedures.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis